Certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-01-14. Anything still debated is marked as such rather than presented as settled.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
=== Recruiting and activating of immune cells === The binding of a BsAb to its target antigens can lead to a variety of effects. The most widely used application of this approach is in cancer immunotherapy, where BsAbs are engineered to simultaneously bind a cytotoxic cell and a target (a tumour cell) to be destroyed. It is possible to observe the bridging effect that BsAbs have on T cell/cancer cell interactions using label-free live cell imaging. Catumaxomab, one of the first trifunctional antibodies approved for therapeutic use, binds both CD3 on cytotoxic T cells and EpCAM on human adenocarcinomas. The Fc region additionally binds to a cell that expresses Fc receptors, like a macrophage, natural killer cell or dendritic cell. Since the Fc region is still intact, this allows for the BsAb to trigger common immune responses when recognized by an Fc receptor, such as antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity.
In the 1950s and 1960s, the Green Revolution aimed to bring modern Western agricultural techniques (like nitrogen fertilizers and pesticides) to Asia. Investments in agriculture, such as fund fertilizers and seeds, increased food harvests and thus food production. Consequently, food prices and malnutrition decreased (as they had earlier in Western nations).
==== The Iberian Peninsula ==== The Normans began appearing in the military confrontations between Christians and Muslims in the Iberian Peninsula since the early eleventh century. The first Norman who appears in the narrative sources was Roger I of Tosny who according to Ademar of Chabannes and the later Chronicle of St Pierre le Vif went to aid the Barcelonese in a series of raids against the Andalusi Muslims c. 1018. Later in the eleventh century, other Norman adventurers such as Robert Crispin and Walter Giffard participated in the probably papal organised siege of Barbastro of 1064. Even after the Norman conquest of England in 1066, the Normans continued to participate in ventures in the peninsula. After the Frankish conquest of the Holy Land during the First Crusade, the Normans began to be encouraged to participate in ventures of conquest in the northeast of the peninsula. The most significant example of this was the incursion of Rotrou II of Perche and Robert Burdet in the 1120s in the Ebro frontier. By 1129 Robert Burdet had been granted a semi-independent principality in the city of Tarragona by the then Archbishop of this see, Oleguer Bonestruga. Several others of Rotrou's Norman followers were rewarded with lands in the Ebro valley by King Alfonso I of Aragon for their services. With the rising popularity of the sea route to the Holy Land, Norman and Anglo-Norman crusaders also started to be encouraged locally by Iberian prelates to participate in the Portuguese incursions into the western areas of the Peninsula.
Sources: en.wikipedia.org
Young's modulus (or the Young modulus) is a mechanical property of solid materials that measures the tensile or compressive stiffness when the force is applied lengthwise. It is the elastic modulus for tension or axial compression. Young's modulus is defined as the quotient of the stress (force per unit area) applied to the object and the resulting axial strain (a dimensionless quantity that quantifies relative deformation) in the linear elastic region of the material. As such, Young's modulus is similar and proportional to the spring constant in Hooke's law, but with dimensions of pressure instead of force per distance. Although Young's modulus is named after the 19th-century British scientist Thomas Young, the concept was developed in 1727 by Leonhard Euler. The first experiments that used the concept of Young's modulus in its modern form were performed by the Italian scientist Giordano Riccati in 1782, pre-dating Young's work by 25 years. The term modulus is derived from the Latin root term modus, which means measure.
=== 1968–1999 === In 1968, Environmental Sciences Corporation was established in Seattle, Washington, manufacturing equipment related to laboratory animals. In 1972, it acquired and took the name of Hazleton Laboratories, a contract laboratory that conducted toxicology testing. In 1977, Corning Inc. purchased a stake in Hazleton and in 1987, it acquired the remainder of the company for $115 million. By 1982, Hazleton was the largest independent biological testing company and life sciences laboratory in the U.S. and the largest laboratory equipment manufacturer worldwide. The company carried out animal toxicology tests of drugs, cosmetics, pesticides, and industrial chemicals, and bred rhesus monkeys and beagles for its own labs, as well as for chemical and drug companies, hospitals, universities and government agencies. It offered chemical analysis of new compound products for various industries, tested chemicals for gene mutations, and carried out research with monoclonal antibodies. It sold the equipment manufacturing unit in the mid-1980s. In 1989, Corning Glass Works acquired G.H. Besselaar Associates, which conducted clinical trials for drug approvals. In 1990, Hazleton acquired Microtest, a molecular toxicology center in York, England. Corning Glass Works changed its name to Corning, and folded Besselaar and Hazelton into a new subsidiary, Corning Lab Services. In 1991, Corning Lab Services acquired SciCor. In 1992, it acquired Philadelphia Association of Clinical Trials.
Detergents, such as SDS or Tween-20, which are used to break open cells and release the DNA. Protease enzymes, such as Proteinase K, which are used to digest proteins that may be binding to the DNA. Phenol and chloroform, which are used to separate the DNA from other cellular components. Ethanol or isopropanol, which are used to precipitate the DNA. Salt, such as NaCl, which is often used to help dissolve the DNA and maintain its stability. EDTA, which inactivates enzymes such as nucleases by chelating (binding) metals ions needed as cofactors. Tris-HCL, which is used to maintain the pH at the optimal condition for DNA extraction.
In June 2019, Pritzker signed into law Senate Bill 25, or the Reproductive Health Act. The act repealed the Illinois Abortion Law of 1975, which penalized doctors for performing abortions considered "unnecessary", and the "Partial-Birth Abortion Ban Act". The new bill ensured the "fundamental right to make autonomous decisions about one's own reproductive health", specifically the right to choose whether to carry a pregnancy to term or to terminate it, and denies a zygote, an embryo, or a fetus "independent rights under the law" of the State of Illinois. Pritzker encouraged other states that had passed restrictions on abortion to reconsider their positions and said that women from other states could access medical services in Illinois. After Dobbs v. Jackson overturned Roe v. Wade in 2022, Illinois became an abortion-access state for people in the South and Midwest whose states ban abortion, with 30% of abortions being for out-of-state residents. Abortions in Illinois increased by over 45% in the year after Roe was overturned, primarily due to patients' traveling from states with abortion bans. In 2024, Pritzker signed the Birth Equity Act, which required Illinois-based health insurance providers to cover abortion care without copayments or deductibles. On June 24, 2026, Pritzker signed the Reproductive Health Records Privacy Act, a law that protects those seeking abortions in Illinois by shielding digital medical records from out-of-state entities, effective July 1, 2027.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.